Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

RCT (n=269) found a significantly improved ASAS20 response for tofacitinib vs placebo at week 16 (56.4% vs 29.4%, p<0.0001). The ASAS40 response was also superior (40.6% vs 12.5%, p<0.0001). Authors state no new potential safety risks for tofacitinib were identified.

Source:

Annals of the Rheumatic Diseases